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Based on existing data and previous work, a series of studies is 
proposed as a basis toward a pragmatic early step in transform-
ing toxicity testing. These studies were assembled into a data-
driven framework that invokes successive tiers of testing with 
margin of exposure (MOE) as the primary metric. The first tier 
of the framework integrates data from high-throughput in vitro 
assays, in vitro-to-in vivo extrapolation (IVIVE) pharmacokinetic 
modeling, and exposure modeling. The in vitro assays are used to 
separate chemicals based on their relative selectivity in interact-
ing with biological targets and identify the concentration at which 
these interactions occur. The IVIVE modeling converts in vitro 
concentrations into external dose for calculation of the point of 
departure (POD) and comparisons to human exposure estimates 
to yield a MOE. The second tier involves short-term in vivo stud-
ies, expanded pharmacokinetic evaluations, and refined human 
exposure estimates. The results from the second tier studies 
provide more accurate estimates of the POD and the MOE. The 
third tier contains the traditional animal studies currently used to 
assess chemical safety. In each tier, the POD for selective chemi-
cals is based primarily on endpoints associated with a proposed 
mode of action, whereas the POD for nonselective chemicals is 
based on potential biological perturbation. Based on the MOE, 
a significant percentage of chemicals evaluated in the first 2 tiers 
could be eliminated from further testing. The framework provides 
a risk-based and animal-sparing approach to evaluate chemical 
safety, drawing broadly from previous experience but incorporat-
ing technological advances to increase efficiency.
Key Words: in vitro and altenatives; biotransformation and 
toxicokinetics; predictive toxicology; risk assessment; safety 
evaluation; exposure.
Shortly after the turn of the century, there was increasing rec-
ognition and acceptance within government agencies that new 
approaches were needed to evaluate the safety of the relatively 
large number of chemicals in commerce and the environment 
(EPA, 2003; Kavlock et al., 2005; Meek and Armstrong, 2007; 
NTP, 2004). Following this recognition, the release of the National 
Research Council’s Report “Toxicity Testing in the 21st Century: 
A Vision and a Strategy” (NRC, 2007) initiated a broad-based 
movement in the toxicology community to reassess how toxicity 
testing and risk assessment are performed. Since the release of the 
report, multiple efforts in the United States and abroad have added 
to the momentum with the shared goal of transitioning toxicity 
testing and risk assessment from an outdated, inefficient, costly, 
and animal-centric process to one that is more efficient, economi-
cal, less animal intensive, and more relevant to human health by 
utilizing new technologies that provide a better understanding of 
the underlying biological system. However, the majority of these 
efforts have focused more on a vision of how things should be 
done rather than the development of a pragmatic path forward that 
can be iteratively refined as greater understanding is achieved.
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NEW TECHNOLOGIES IN TOXICITY TESTING
Over the past 5 years, a series of studies has been conducted 
that together may contribute first steps toward executing the 
shared vision. This article considers the implications of these 
studies and develops a new, data-driven tiered toxicity testing 
framework with potentially broad, international application 
across multiple regulatory agencies. The framework evolved 
from tiered approaches developed previously to address regula-
tory mandates to prioritize and assess large numbers of sub-
stances (Meek and Armstrong, 2007; Meek et al., 2011). The 
primary application of the proposed framework is for chemi-
cals with little or no safety-related data. In the United States, 
the proposed framework could, for example, be applied to new 
and legacy manufactured chemicals regulated under the Toxic 
Substances Control Act (TSCA). Conceptually, it could also be 
applied to other nonpharmaceutical chemicals that have defined 
toxicity testing requirements, such as pesticides. In Europe, the 
proposed framework could be applied to identify substances 
of concern within Registration, Evaluation, Authorization and 
Restriction of Chemicals (REACH) that may have adverse 
effects that are not indicated in the basic information require-
ments linked to production volume.
TIEr 1
The first tier of the proposed framework consists of 5 com-
ponents—(1) use of high-throughput in vitro assays to separate 
chemicals into selective and nonselective modes of action; (2) 
in vitro genotoxicity assays to identify potential genotoxic and 
nongenotoxic chemicals; (3) in vitro-to-in vivo extrapolation 
(IVIVE) pharmacokinetic modeling to convert in vitro assay 
concentrations to applied doses; (4) high-throughput exposure 
modeling to estimate human exposures to chemicals; and (5) 
calculation of a margin of exposure (MOE) (Fig. 1). The data 
collection and analysis associated with each of these com-
ponents would ideally occur simultaneously for inclusion in 
a Tier 1 data package associated with each chemical, analo-
gous to the chemical dossiers currently being assembled for 
FIg. 1. A flowchart outlining Tier 1 in the proposed framework. The green boxes illustrate the Tier 1 data package that includes experimental data and com-
putational modeling results that serve as inputs into the framework. The yellow boxes are separate chemical categories determined by the in vitro genotoxicity 
assays and the high-throughput in vitro screening assays. For the selective chemicals, the red box represents the determination of the tentative mode of action based 
on which high-throughput in vitro assays were selectively activated or inhibited. The blue and orange boxes represent the estimation of the point of departure and 
MOE using additional pharmacokinetic and exposure information, respectively. For those chemicals with a MOE greater than a defined cutoff, no further testing is 
performed, and Tier 1 reference values are published. Chemicals with a MOE less than the cutoff are advanced to Tier 2. Abbreviation: MOE, margin of exposure.
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REACH. Within the current framework, the high-throughput 
in vitro screening would be composed of assays that are similar 
to those employed in the ToxCast project (Houck et al., 2009; 
Judson et al., 2010; Knudsen et al., 2011; Martin et al., 2010; 
Reif et al., 2010; Rotroff et al., 2010a). The in vitro ToxCast 
assays are primarily repurposed biochemical and cell-based 
assays used in drug discovery and cover 327 genes and 293 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
(Kavlock et al., 2012). The details surrounding their selection 
and application have been discussed in the publications cited 
earlier. Although this selection of in vitro assays may not be 
ideal for covering the mechanistic landscape of chemically 
mediated toxicity, the ToxCast data set is the largest currently 
available for establishing the associations underlying this 
framework and provides a significant (though recognizably 
imperfect) starting point for a pragmatic path forward that can 
be refined as additional experience is acquired.
In Vitro Assays for Bioactivity
In the ToxCast phase I  effort, 309 unique chemicals were 
screened in more than 600 in vitro assays. The 309 chemi-
cals were primarily pesticides and high-production volume 
chemicals for which significant in vivo animal testing has 
been performed (Judson et  al., 2009; Martin et  al., 2009a). 
Although prediction of specific in vivo hazards with the cur-
rent set of ToxCast in vitro assays is limited (Thomas et  al., 
2012a; Wetmore et al., 2012a), the in vitro assays do provide a 
broad biological profile of the potential proximal biochemical 
and cellular targets for a chemical. Instead of using the high-
throughput in vitro assays to predict hazard, the initial role of 
high-throughput in vitro toxicity screening in our framework 
is to separate chemicals into either those that cause toxicity 
primarily through nonselective interactions with cells and cel-
lular macromolecules or those that act through more selective 
interactions (eg, receptor-mediated chemicals).
To demonstrate how chemicals could be separated into these 
categories, the ToxCast phase I data were analyzed for surro-
gate measures of selectivity. Additional work in this area will 
need to be performed to identify which selective interactions 
are important for toxicity. The ToxCast in vitro assays were 
first grouped by gene to eliminate redundancy. For example, all 
of the in vitro assays evaluating the binding or transcriptional 
activation of estrogen receptor alpha (ESR1) were grouped 
together. The in vitro assays that did not correspond to a spe-
cific gene (eg, general cytotoxicity assays) were removed from 
the analysis. If any of the in vitro assays associated with a gene 
possessed an AC
50
 value (concentration at 50% of maximum 
activity), then the chemical was considered to have activity (ie, 
either activates or inhibits) toward that gene. Thus, the more 
genes with AC
50
 values, the less selective a chemical would 
be. For the ToxCast phase I  chemicals, approximately 80% 
of chemicals have activity toward 10 or more genes, and the 
average chemical has activity toward approximately 20 genes 
(Fig. 2A).
A complementary measure of selectivity expands on this con-
cept and takes into consideration the dose range across which 
the different in vitro assays were activated. For each chemical, 
the in vitro assays were again grouped by gene, and the in vitro 
assays that did not correspond to a specific gene were removed 
from the analysis (eg, general cytotoxicity assays). The potency 
of each chemical toward a specific gene was summarized by 
taking the minimum AC
50
 value among the associated in vitro 
assays. For example, if there were 5 in vitro assays evaluating 
the binding or transcriptional activation of ESR1, the potency 
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FIg. 2. Cumulative frequency plots summarizing the selectivity of the ToxCast phase I chemicals across the high-throughput in vitro assays. The in vitro 
assays were grouped by gene to eliminate redundancy. A, The number of genes with an AC
50
 value for each chemical. This represents the number of genes activated 
or inhibited by a chemical at any concentration. All 309 ToxCast phase I chemicals were used in this analysis. B, The ratio between the minimum AC
50
 and the 
10th percentile for each chemical. This represents the ratio between the concentration at which the most sensitive gene-based assay is activated, and the concentra-
tion at which 10% of the gene-based assays are activated. Only 173 ToxCast phase I chemicals activating or inhibiting > 20 gene-based high-throughput in vitro 
assays were used in this analysis.
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value for the most sensitive assay was selected. For each chemi-
cal, the summary values for each gene were then sorted, and 
the lowest summary value across all genes was divided by the 
10th percentile. In other words, for each chemical, the potency 
of the in vitro assay for the most sensitive gene was divided 
by the relative potency when 10% of the genes were affected. 
According to this measure of selectivity, approximately 80% of 
the ToxCast phase I chemicals have a ratio of 3 or less between 
the most sensitive gene target and the 10th percentile (Fig. 2B). 
Taken together, these data suggest that the majority of chemi-
cals represented in the ToxCast phase I  library likely act via 
nonselective interactions with cellular macromolecules. These 
results may not be that surprising given that most chemicals in 
the ToxCast phase I library were nonpharmaceuticals and were 
developed either for their functional properties in a range of 
different products or pesticidal qualities and not optimized to 
interact specifically with a target protein.
In Vitro Assays for Genotoxicity
In addition to separating chemicals based on selectivity, 
chemicals are also grouped based on their genotoxic potential. 
This second screen was included as a practical consideration 
because most regulatory organizations either label or deal with 
substances that are likely to be carcinogenic through a muta-
genic mode of action (MOA) differently than those considered 
not to be genotoxic. The in vitro assays for genotoxicity within 
the proposed framework include the bacterial reverse muta-
tion test and the mammalian cell micronucleus test. These 2 
in vitro genotoxicity assays cover the 3 critical genetic end-
points implicated in carcinogenesis and heritable diseases, 
namely gene mutations, and structural and numerical chromo-
some alterations. An expert panel convened by the European 
Food Safety Authority (EFSA) concluded that the inclusion 
of additional in vitro mammalian cell tests apart from these 2 
assays would “significantly reduce specificity with no substan-
tial gain in sensitivity” (EFSA, 2011). This is consistent with 
previous recommendations of multiple regulatory agencies and 
the International Conference on Harmonization (ICH) for reg-
istration of pharmaceuticals (HC, 2000). Adaptations have been 
proposed that reduce the number of false positives in the mam-
malian cell genotoxicity assays (Fowler et al., 2012). If the 2 
in vitro genotoxicity assays are negative, the chemical is placed 
in the nongenotoxic category, whereas positive results in both 
assays would classify the chemical as potentially genotoxic. If 
a chemical is positive in one of the in vitro assays, the chemical 
would be classified as potentially genotoxic and additional in 
vitro or in vivo assays could be performed to confirm the clas-
sification. For example, if a chemical is negative in the bacte-
rial reverse mutation test and positive in the mammalian cell 
micronucleus test, an in vivo micronucleus analysis could also 
be performed to confirm the clastogenicity as recommended in 
the standard ICH guidelines (Müller et al., 1999). Ideally, the 
in vivo micronuclei studies would be performed in Tier 2 on the 
same animals as the transcriptomic analysis using red blood 
cell micronuclei as the endpoint. If a chemical is positive in the 
bacterial reverse mutation test and negative in the mammalian 
cell micronucleus test, an in vivo gene mutation study could be 
performed using 28-day exposures of transgenic rodents carry-
ing mutation reporter genes (OECD, 2011), but this is not cost 
effective for many chemicals at this point in time.
In Vitro Pharmacokinetic Assays and IVIVE Modeling
The internal dose of a chemical is an important determinant 
of toxicity. To incorporate pharmacokinetics into the frame-
work, data from in vitro hepatic metabolic clearance and plasma 
protein binding assays are included in the Tier 1 data package. 
These 2 pharmacokinetic parameters are critical for estimating 
steady-state blood concentrations. In previous studies, experi-
mental data from the in vitro pharmacokinetic assays were used 
to parameterize an IVIVE model to estimate the daily human 
oral dose, called the oral equivalent dose, necessary to produce 
steady-state in vivo blood concentrations equivalent to the in 
vitro AC
50
 value for each of the high-throughput in vitro assays 
(Rotroff et al., 2010b; Wetmore et al., 2012b). Oral equivalent 
dose values calculated using this approach are inherently con-
servative due to various assumptions in the IVIVE modeling 
(Rotroff et  al., 2010b; Wetmore et  al., 2012b). Monte Carlo 
sampling was also incorporated into the IVIVE model to 
account for interindividual variability and as a basis to derive 
an oral equivalent dose that represents the 95th percentile of 
the population. A  similar approach takes place in our frame-
work and when appropriate, other biokinetic factors within the 
in vitro assays will be taken into account (Blaauboer, 2010). 
Human equivalent concentrations could also be calculated to 
allow comparisons to air exposure levels.
Selective-Acting Chemicals and MOA
For the selective chemicals, the high-throughput in vitro 
assays are used to identify key events in a potential MOA. 
As previously defined, the MOA is a biologically plausi-
ble series of key events leading to an outcome that could be 
adverse (Sonich-Mullin et  al., 2001). Key events are empiri-
cally observable steps that are critical to the outcome. Although 
originally and often simply conceptualized as a linear series of 
key events, a MOA actually involves interdependent networks 
of events with feedback loops. A  weight of evidence for the 
hypothesized MOA is established based on modified Bradford 
Hill considerations including dose response and temporal con-
cordance of key events, consistency and specificity, and bio-
logical plausibility (Boobis et al., 2006, 2008).
For application to selective chemicals in Tier 1 of the pro-
posed framework, the key event must be triggered at doses 
lower than or equal to doses at which the adverse outcome is 
observed (ie, dose concordance between a key event and the 
adverse outcome). An example of this approach has been pro-
vided for the relationship between in vitro peroxisome prolifer-
ator–activated receptor alpha (PPARA) activation and rat liver 
proliferative lesions and liver tumors (Wetmore et al., 2012a). 
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Among a subset of ToxCast phase I chemicals, 8 were active 
in the in vitro PPARA assays and cause proliferative lesions in 
the livers of rats, while 4 also cause rat liver tumors. For each 
chemical, the in vivo-derived lowest effect level (LEL) and no 
effect level for rat liver proliferative lesions and tumors were 
overlaid with the oral equivalent dose values for the 3 high-
throughput in vitro assays measuring PPARA-related activation 
(Fig. 3). In all cases, activation of the PPARA in vitro assays 
occurred at or below the dose for the in vivo effects, thereby 
demonstrating dose concordance between this potential key 
event and the adverse outcome. A similar approach is taken in 
the proposed framework. From these selectively activated or 
inhibited assays, probable key event(s) will be determined and 
the oral equivalent dose value from a relevant in vitro assay will 
be compared with doses causing the associated in vivo adverse 
outcome (when available).
Apart from dose concordance, the biological relevance link-
ing the in vitro assay to the in vivo adverse outcome will also 
be qualitatively assessed. If the in vitro assay representing the 
key event demonstrates dose concordance and biological rel-
evance, the oral equivalent dose value will be used as the point 
of departure (POD) in a dose-response assessment. It is antici-
pated that there will be a limited number of MOAs that will 
be identified in Tier 1 for the selective chemicals. The MOAs 
will have a defined set of criteria based on chemicals that are 
known to act through those key events. Additional MOAs will 
be added as our biological knowledge improves and the assay 
suite is refined.
Nonselective Chemicals and Biological Perturbation
Identifying the MOA will generally be neither efficient nor 
economical for the nonselective chemicals because the chemi-
cals will interact with and perturb multiple cellular processes. 
In a previous study, rat-specific oral equivalent doses were cal-
culated for 59 ToxCast phase I chemicals and compared with 
LEL values for a variety of in vivo apical responses (Wetmore 
et al., 2012a). Although not significantly correlated (r2 = .046), 
the oral equivalent dose for the most sensitive in vitro assay was 
less than the LEL for the most sensitive rat in vivo endpoint for 
approximately 95% of the chemicals (Fig. 4A). The LEL values 
spanned 38 unique in vivo endpoints across multiple tissue and 
organ systems and across reproductive, chronic, and develop-
mental study types. The median difference between the most 
sensitive in vitro assay and the most sensitive LEL value was 
66-fold (Fig.  4B). These results indicate that the most sensi-
tive in vitro assay was protective regardless of the nature of the
adverse outcome and that bioactivity based on the oral equiva-
lent dose for the most sensitive in vitro assay could be used as a
reasonable estimate of the POD for the nonselective chemicals
in a dose-response assessment.
Human Exposure Characterization
The final component of the Tier 1 data package relates to 
exposure. An understanding of human exposure is critical for 
placing the dose-response data for toxicity into context and 
ultimately assessing health risks. Human exposure estimates 
FIg. 3. Comparison of in vivo low effect and no effect doses for rat liver proliferative lesions and the in vitro PPARA-activating oral equivalent doses in the 
ToxCast phase I assays. The in vivo effects of 8 chemicals were plotted as LEL (blue triangles) and NEL (yellow triangles). If liver tumors were observed, a red 
triangle was placed at the tumorigenic LEL. The in vitro oral equivalent doses were overlaid for the PPARA transactivation assay in HepG2 cells (white circles) 
(Martin et al., 2010) and PPARA-regulated HMGCS2 gene expression changes in primary human hepatocytes at 24 h (white squares) and 48 h (white diamonds) 
(Rotroff et al., 2010a). The oral equivalent doses for each assay were calculated at the 1 and 10µM concentrations where intrinsic clearance was measured and 
connected with a solid line. The gray bars span 10-fold below the NEL and 10-fold above the highest of the LEL to illustrate potential uncertainties in the approxi-
mations associated with the oral equivalent doses. The graph and associated data are from Wetmore et al. (2012a). Abbreviations: LEL, low effect levels; NEL, no 
effect levels; PPARA, peroxisome proliferator–activated receptor alpha.
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can be obtained from multiple sources and are associated with 
varying levels of uncertainty, depending principally on the 
complexity and accuracy of input data and model assump-
tions. Simple surrogates such as use and emission profiling and 
physicochemical properties offer potential to reasonably dis-
criminate amongst chemicals with respect to exposure potential 
(Arnot et al., 2012; Meek and Armstrong, 2007; Meek et al., 
2011).
For some of the Tier 1 chemicals, human exposure esti-
mates can be derived from biomonitoring data such as the U.S. 
National Health and Nutrition Examination Survey (NHANES) 
(CDC, 2009). Measurements of parent chemical concentrations 
in the blood or urinary metabolite concentrations can be used to 
infer exposure concentrations using reverse dosimetry methods 
(Tan et al., 2007). Using Monte Carlo sampling, probabilistic 
information about pharmacokinetics and exposure patterns can 
be included to estimate variability in the exposure distribution 
across a diverse population (Tan et al., 2007). In Tier 1 of our 
framework, a conservative 95th percentile upper confidence 
bound on the exposure estimate is used, where available.
For chemicals without biomonitoring data, it is proposed to 
use a high-throughput exposure modeling that has been devel-
oped by combining existing environmental fate and transport 
models (ie, far field) with an empirical adjustment for indoor or 
consumer exposure (ie, near field) (Wambaugh et al., 2013). In 
addition to a high-level assessment of consumer use, physico-
chemical properties and an estimate of environmental release 
are required as inputs to the model. The approach was calibrated 
using 82 chemicals from NHANES and then used to predict 
human exposures for 1,936 chemicals. The approach provides 
uncertainty bounds on the aggregate exposure estimates. The 
95th percentile upper confidence bound of the exposure esti-
mate is utilized in our framework.
MOEs
The human exposure estimates are combined with the POD 
from the dose-response assessment to calculate a MOE. For 
the components of the framework discussed above, the MOE 
is based on administered dose. A second alternative is the cal-
culation of MOE based on internal dose using human biomon-
itoring data. For this alternative, concentrations in blood are 
directly compared with the concentrations in the in vitro assays 
so as to provide a direct measure of a MOE (Aylward and 
Hays, 2011; Aylward et al., 2013). Although not all chemicals 
are amenable to biomonitoring measurements, the advantage 
of this approach is that it eliminates inherent uncertainty in the 
pharmacokinetic and exposure modeling. Interindividual vari-
ability could be incorporated by using either the percentiles of 
the measured distribution in large biomonitoring studies (CDC, 
2009) or estimated from smaller studies using pooled samples 
(Caudill, 2010, 2012).
Regardless of whether the MOE is calculated using admin-
istered or internal dose, the MOE is the primary metric for 
determining whether a substance advances on for consideration 
in subsequent tiers. For the selective chemicals, the MOE is 
calculated relative to the oral equivalent dose from the in vitro 
FIg. 4. A comparison of ToxCast in vitro assay possessing the lowest oral equivalent dose with the in vivo response possessing the lowest LEL for each 
chemical. A, Scatter plot of the log-transformed minimum LEL in ToxRefDB (y-axis) versus the minimum oral equivalent dose among the approximately 600 
high-throughput in vitro ToxCast assays (x-axis) for each chemical. A subset of 59 ToxCast phase I chemicals were evaluated. B, Histogram and summary statis-
tics of the log
10
-transformed ratios of the minimum LEL from the guideline animal studies in ToxRefDB divided by the minimum oral equivalent dose among the 
approximately 600 high-throughput in vitro assays. Nontransformed values for each of the summary statistics are provided in parentheses. The graph and associ-
ated data are from Wetmore et al. (2012a). Abbreviation: LEL, low effect level.
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assay(s) associated with the proposed key event. For the non-
selective chemicals, the MOE will be calculated relative to the 
oral equivalent dose for the most sensitive in vitro assay. For 
those chemicals with a MOE greater than some defined cut-
off, no further testing would be required, whereas chemicals 
with a MOE below the cutoff would progress on to Tier 2. In 
a previous study on the ToxCast phase I chemicals (Wetmore 
et al., 2012a), a Tier 1 MOE cutoff of > 100 would eliminate 
additional testing on approximately 40% of chemicals, whereas 
a MOE cutoff of > 1000 would eliminate additional testing on 
approximately 25% of chemicals (Fig. 5). Although the MOE 
cutoff will be primarily set through policy decisions and not 
necessarily based solely on scientific criteria, it should be set 
to provide adequate protection for susceptible subpopulations.
Reference Values
For those chemicals that do not advance to the next tier, Tier 
1 reference values could be used to provide exposure guide-
lines. For certain regulatory agencies these could be considered 
screening-level values, whereas other agencies may wish to 
apply them in alternative ways. For the nongenotoxic chemi-
cals, the POD and associated lower confidence bound can be 
divided by a set of uncertainty/safety factors to derive a Tier 1 
reference value as a basis to provide health-related guidance. 
A previous study using in vitro data has provided one possible 
approach (Judson et al., 2011). For the genotoxic chemicals, 
the POD and associated lower confidence bound can be divided 
by uncertainty/safety factors, or, alternatively, a linear, no 
threshold dose-response extrapolation could be applied. In this 
case, the POD could be assumed to be equivalent to a defined 
increase in adverse response (eg, 10%) and used to calculate a 
Tier 1 slope factor. However, it should be noted that activation 
of the in vitro assays analyzed here cannot yet be quantitatively 
linked to a specific incidence in the in vivo adverse response.
Chemicals Not Amenable to In Vitro Screening
Although efforts are underway to broaden the applicability of 
high-throughput in vitro screening platforms, certain chemicals, 
such as volatile substances, those not soluble in dimethyl sulfox-
ide or those that bind avidly to plastic, are currently not readily 
amenable for high-throughput in vitro screening. In the proposed 
framework, these chemicals would be identified using an initial 
structure-activity relationship or molecular properties filter and 
are automatically directed to Tier 2 for evaluation. No measure 
of selectivity would be available for these chemicals, and they 
would be assumed to act through nonselective mechanisms.
TIEr 2
The second tier of the proposed framework consists of 5 
components—(1) short-term in vivo transcriptomic studies 
to identify the transcriptional POD values for nonselective 
chemicals; (2) in vivo MOA studies to identify POD values for 
selective chemicals; (3) in vitro and in vivo pharmacokinetic 
studies to improve linkage between internal and applied dose; 
(4) refined human exposure estimates; and (5) calculation of a
MOE (Fig. 6). Similar to the first tier, the data collection and
FIg. 5. Cumulative frequency plot of the ratio between in vitro bioactivity relative to human exposure in the most highly exposed subpopulation for the 
ToxCast phase I chemicals. The MOE was calculated by comparing the minimum oral equivalent dose across the approximately 600 high-throughput in vitro 
ToxCast assays using human pharmacokinetic measurements and in vitro-to-in vivo extrapolation modeling with the exposure estimates for the most highly 
exposed subpopulation. The graph and associated data are reproduced from Wetmore et al. (2012a). Abbreviation: MOE, margin of exposure.
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analysis associated with each of these components would ide-
ally occur simultaneously for inclusion in a cohesive Tier 2 
data package. The data requirements would be different for the 
selective and nonselective chemicals.
Selective-Acting Chemicals and MOA
Focused in vivo MOA studies would be performed on the 
selective chemicals to evaluate the putative MOA defined in 
Tier 1 and would be defined by the type of MOA proposed. 
For proposed nuclear receptor agonists such as the constitu-
tive androstane receptor, pregnane X receptor, or PPARA, these 
studies could include knockout and humanized rodent models. 
For proposed estrogen receptor agonists, these studies may also 
include standard in vivo studies such as the immature rat utero-
trophic assay (OECD 440). Following the in vivo MOA stud-
ies and consideration of the weight of evidence, qualitative and 
quantitative human concordance would be evaluated (Boobis 
et al., 2008). The POD for relevant MOAs would be determined 
based on the associated endpoints in the in vivo studies, but 
scaled, taking into account relevant kinetic and dynamic data.
Nonselective Chemicals and Biological Perturbation
The premise for analysis of nonselective chemicals has been 
developed based on the results of a series of previous studies 
examining the relationship between transcriptional and apical 
responses (Thomas et al., 2007, 2011, 2012b, 2013). Both non-
cancer and cancer apical responses were analyzed using bench-
mark dose (BMD) methods to identify PODs. The dose response 
for changes in gene expression was also analyzed using BMD 
methods, and the responses were grouped based on signaling 
pathways. In a comparison of transcriptional BMD values for 
the most sensitive pathway with BMD values for the noncancer 
and cancer apical endpoints, there was a high degree of cor-
relation (Thomas et al., 2012b) (Fig. 7). The correlation was 
also robust across multiple time points (Thomas et al., 2013). 
In this proposed framework, dose-response studies would be 
FIg. 6. A flowchart outlining Tier 2 in the proposed framework. The green boxes illustrate the Tier 2 data package that includes experimental data and compu-
tational modeling results that serve as inputs into the framework. The chemical categories determined by the in vitro genotoxicity assays and the high-throughput 
in vitro screening assays are retained from Tier 1. For the selective chemicals, the light blue box represents the determination of the human relevance of the mode 
of action. The blue and orange boxes represent the estimation of the point of departure and MOE using expanded pharmacokinetic and exposure information, 
respectively. For those chemicals with a MOE greater than a defined cutoff, no further testing is performed, and Tier 2 reference values are published. Chemicals 
with a MOE less than the cutoff are advanced to Tier 3. Abbreviation: MOE, margin of exposure.
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performed on the chemical at any single time point between 
5 days and 13 weeks in mice and rats of both sexes. A battery of 
8 tissues that include those most frequently impacted in rodent 
cancer bioassays (liver, lung, mammary gland, stomach, vascu-
lar system, kidney, hematopoietic system, and urinary bladder) 
would be harvested. These 8 tissues cover 92% and 82% of tar-
gets for all mouse and rat carcinogens, respectively (Gold et al., 
2001). For noncancer effects, a previous analysis of 69 differ-
ent pesticides demonstrated that adverse responses in a chronic 
rat bioassay generally occurred at lower doses than either a rat 
2-generation reproductive study or a rat developmental toxicity
study (Dourson et al., 1992). In addition, potential reproduc-
tive and developmental toxicants could be identified based on
consideration of weight of evidence of available data includ-
ing structure activity modeling (Blackburn et  al., 2011). For
chemicals flagged for these potential responses, additional
tissues and alternate study designs (eg, OECD 421) would be
incorporated to cover potential reproductive and developmental
effects. Gene expression microarray analysis on these tissues
would allow the estimation of pathway transcriptional BMD
and BMDL values. The signaling pathway with the lowest tran-
scriptional BMD value among the analyzed tissues would be
used to derive the POD.
In Vivo and In Vitro Pharmacokinetic Studies and Modeling
The pharmacokinetic data from Tier 1 would also be 
expanded through focused in vitro studies and the collection of 
additional samples within the existing in vivo studies. Potential 
metabolites of each chemical would be identified using rodent 
and human microsomes, S9, and plasma. Recent advances in 
semiautomated metabolite identification have been made by 
combining in silico metabolite prediction software with ultra-
high pressure liquid chromatography and mass spectral analy-
sis (Bonn et al., 2010). In essence, computational approaches 
are used to align the raw mass spectral data with a predicted site 
of metabolism in order to assign the structure of a metabolite. 
In our framework, these studies are performed to qualitatively 
identify probable metabolites in both the rodent and human. 
Reactive metabolites will also be evaluated using primary 
hepatocytes for analysis of lipid peroxidation, reactive oxygen 
species generation, and glutathione depletion.
Apart from the metabolite characterization, blood samples 
will be collected in either the in vivo mode-of-action studies 
for the selective chemicals or the in vivo transcriptomic studies 
for the nonselective chemicals. A previous study has demon-
strated that the collection of blood samples at 3 specific time 
points during a single day of a repeat dose study was sufficient 
to estimate systemic bioavailability of a chemical (Saghir et al., 
2006). The human volume of distribution of each chemical 
will be estimated using quantitative structure-activity relation-
ships (Peyret and Krishnan, 2011; Peyret et al., 2010; Poulin 
and Theil, 2002; Rodgers and Rowland, 2006, 2007; Rodgers 
et al., 2005), and the oral bioavailability will be estimated using 
the in vitro bidirectional permeability assay with Caco-2 cells 
(Wetmore et al., 2012b). Together with the metabolic clearance 
and plasma protein binding data from the Tier 1 studies, the 
FIg. 7. Scatter plots of the relationship between the BMD values for (A) cancer-related apical endpoints or (B) noncancer apical endpoints and transcriptional 
BMD values for the most sensitive signaling pathway following 13 weeks of exposure. The data points were colored based on the target tissue, and symbol shape 
represents species. The black line dissecting the graph indicates equivalent apical and transcriptional BMD values. The red lines represent 10-fold difference 
between the BMD values. Correlation coefficients (r) and associated p value are included in the lower right hand corner of each panel. The median log
2
 ratio of 
the apical-to-transcriptional BMD values is provided in the upper left hand corner. The antilog of the transformed ratio is provided in parentheses. The graph and 
associated data are from Thomas et al. (2013). Abbreviation: BMD, benchmark dose.
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combined data will be used to develop pharmacokinetic models 
to define the administered dose in humans leading to the active 
internal doses seen in the Tier 2 studies.
Human Exposure Characterization
Human exposure estimates from Tier 1 could potentially be 
refined through a combination of experimental measurements 
of physical-chemical properties and environmental degradation 
rates, refined release rates, detailed consumer and indoor use 
profiling, product formulation data, environmental and house-
hold exposure factor estimates, and targeted biomonitoring stud-
ies. The fate and transport models used for the high-throughput 
exposure modeling in Tier 1 rely heavily on physical-chemical 
properties, environmental half-lives, and release rates. For 
many chemicals, the physical-chemical properties and environ-
mental half-lives are not experimentally available and have to 
be estimated using quantitative structure-activity relationships 
(Wambaugh et al., 2013). Higher throughput methods are avail-
able for measuring both physical-chemical properties (Kerns, 
2001) and the degradation half-lives in some environmental 
media (Hussain et al., 2007). In our proposed framework, these 
higher throughput methods could be applied to all Tier 2 chemi-
cals. In addition, more accurate industrial release rates could be 
obtained from industry. The combination of these data may be 
used to reduce the uncertainty in the fate and transport models.
To refine the near-field component of the exposure estimates, 
one option is to obtain more detailed consumer and indoor use 
profiles and product formulation data. These use profiles and 
formulation data could be aggregated from existing online 
databases such as the National Library of Medicine (NLM) 
Hazardous Substances Data Bank, NLM Household Products 
Database, Walmart’s online material safety data sheets search 
engine, U.S. Environmental Protection Agency’s (EPA) 
Exposure Factor Handbook (EPA, 2011), and the Substances 
in Products in the Nordic Countries (SPIN) database. A  sig-
nificant amount of the exposure-related data aggregation is 
currently underway (Egeghy et  al., 2012; Mattingly et  al., 
2012). In the proposed framework, the more detailed use pro-
file and product formulation data could potentially be used to 
select relevant consumer exposure models that exist for specific 
exposure scenarios (Kephalopoulos et al., 2007). The resulting 
near-field exposure estimates could be combined with the far-
field exposures to obtain an aggregated exposure estimate.
MOEs
Similar to Tier 1, the human exposure estimates will be 
combined with the POD from the in vivo dose-response studies 
to calculate a MOE based on administered dose. Within Tier 
2, additional alternatives could be explored to integrate high-
throughput biomonitoring studies in order to calculate a MOE 
based on internal dose. Advances in analytical chemistry and 
Fourier transform mass spectrometry have enabled what has 
been termed “high-performance metabolic profiling” (Johnson 
et al., 2010; Park et al., 2012; Soltow et al., 2011). Using these 
methods, up to 7,000 chemicals can be measured in 20 µl of 
biofluids in 20 min (Soltow et  al., 2011). The high-perfor-
mance metabolic profiling could be applied to biomonitoring 
samples from a range of different subpopulations, and mass 
labeled standards could be used to quantify specific chemicals 
of interest. The concentrations in the human blood samples 
would then be compared with estimated blood concentrations 
at the POD in the in vivo transcriptomic or MOA studies to 
provide a MOE.
Regardless of whether the MOE is calculated using admin-
istered or internal dose, the POD for the selective chemicals 
will be based on the associated endpoints in the in vivo MOA 
studies, whereas the POD for the nonselective chemicals will 
be derived from the signaling pathway with the lowest tran-
scriptional BMD value across all analyzed tissues. For those 
chemicals with a MOE greater than a defined cutoff, no fur-
ther testing would be required, whereas chemicals with a MOE 
below the cutoff would progress on to Tier 3. Using data from 
ToxRefDB on the in vivo LEL values for the ToxCast phase 
I chemicals (Knudsen et al., 2009; Martin et al., 2009a,b) and 
the corresponding human exposure estimates (Rotroff et  al., 
2010b; Wetmore et al., 2012b), MOE values were calculated 
using the minimum in vivo LEL value (ie, the most sensitive in 
vivo endpoint) and the exposure estimate for the most highly 
exposed subpopulation. Assuming that this ratio is representa-
tive of the MOE values that will be obtained from Tier 2 in our 
proposed framework, a MOE cutoff of > 100 would eliminate 
additional testing on approximately 97% of chemicals, whereas 
a MOE cutoff of > 1000 would eliminate testing on approxi-
mately 85% of chemicals (Fig. 8).
Reference Values
For those chemicals that are set aside from additional test-
ing, Tier 2 reference values could be published to provide 
exposure guidelines. Similar to those described for Tier 1, 
the Tier 2 reference values may have different applications 
among regulatory agencies. For the nongenotoxic chemi-
cals, the POD and associated lower confidence bound can be 
divided by a set of uncertainty/safety factors to derive a Tier 
2 reference value as a basis to provide health-related guid-
ance. For the genotoxic chemicals, the POD and associated 
lower confidence bound can be divided by uncertainty/safety 
factors, or, alternatively, a linear, no threshold dose-response 
extrapolation could be applied. The POD for the most sen-
sitive pathway among the analyzed tissues could be used as 
the equivalent to the BMDL
10
 for a tumor response (ie, the 
lower confidence limit of the BMD associated with a 10% 
increased risk of tumors). The rationale for this equivalence is 
that our data showed that transcriptional BMD values for the 
most sensitive pathway were, on average, within a factor of 2 
of the BMD
10
 values for tumor responses in the correspond-
ing rodent bioassays (Thomas et  al., 2013). The pathway 
transcriptional BMDL value could then be used to estimate a 




The toxicity testing proposed for chemicals passing into Tier 
3 is not explicitly defined but would be conceptually equiva-
lent to the traditional in vivo studies performed on high-value 
chemicals with significant potential for human exposure. 
Alternatively, they would be specified based on understanding 
of the toxicological profile acquired in lower tier testing. These 
studies could include rodent cancer bioassays, developmental 
toxicity studies, and reproductive toxicity studies. Depending 
on the MOE cutoff values imposed, it is anticipated that the 
majority of chemicals will be screened out in the preceding tiers 
and the estimated number of chemicals requiring these studies 
would be between 3% and 15%. Testing for these remaining 
compounds could be prioritized by endpoint and compounds 
based on the results from both Tier 1 and 2 studies.
SuMMary
The proposed framework integrates data from new technolo-
gies into toxicity testing using what is currently the best avail-
able science. The proposed framework provides a risk-based, 
efficient, and animal-sparing approach to evaluate chemical 
safety. It is consistent with and draws broadly from previous 
experience in risk assessment but incorporates recent advances 
in technology to increase efficiency. The framework relies on 
the initial separation of chemicals into selective and nonselec-
tive MOAs. The prevailing thought is that the MOA approach 
can be efficiently applied to all chemicals. In our view, apply-
ing the MOA approach to the nonselective chemicals is neither 
practical, scientifically justifiable, nor consistent with evolving 
experience in increasing efficiency in risk assessment. First, 
imposing an MOA approach on these chemicals would waste 
valuable resources and unnecessarily delay decision making 
because each MOA requires agreement on the underlying key 
events followed by extensive peer review. Second, for chemi-
cals which interact with numerous molecular targets in a cell, 
identifying a prevailing MOA among many operating in paral-
lel will be a complex and potentially uncertain process. Thus, 
these efforts should be focused on the selective chemicals 
where a series of standardized MOAs could be developed that 
are associated with specific cellular targets.
A shift in thinking will also be required for the nonselec-
tive chemicals. The current hazard-based labeling approach 
that relies on apical responses will need to be transitioned to a 
“region of safety” approach where the most sensitive adverse 
apical effect is not known, but disruption of important biologic 
processes can be measured and the dose response character-
ized. The subsequent decisions are based on potential biologi-
cal perturbations (Andersen and Krewski, 2010). This shift in 
thinking may be more challenging to implement due to the 
entrenched reliance on apical responses, the potentially con-
servative nature of utilizing molecular perturbations as PODs, 
and the difficulty in associating molecular perturbations with 
actual risk. To increase experience in using these approaches, 
the proposed framework could be tested in human health 
FIg. 8. Cumulative frequency plot of the ratio between the in vivo LEL relative to human exposure in the most highly exposed subpopulation for ToxCast 
phase I chemicals. The MOE was calculated by comparing the minimum LEL value of the guideline animal studies in ToxRefDB (Knudsen et al., 2009; Martin 
et al., 2009a,b) divided by the exposure estimates for the most highly exposed subpopulation (Wetmore et al., 2012b). Abbreviations: LEL, low effect level; MOE, 
margin of exposure.
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risk assessment programs tasked with evaluating chemicals 
with limited toxicity data, such as the U.S. Environmental 
Protection Agency’s (EPA) Superfund Health Risk Technical 
Support Center (STSC; http://www.epa.gov/superfund/health/
research.htm). This program evaluates chemicals of interest to 
Superfund that commonly possess limited toxicity data com-
pared with the generally more data-rich chemicals assessed by 
the EPA’s Integrated Risk Information System (IRIS). Once a 
critical mass of chemicals has been evaluated, a reassessment 
of the framework would identify the strengths and limitations 
as well as incorporate any subsequent advances in technology 
or biological knowledge.
Several organizations have proposed using high-throughput 
in vitro assays for prioritizing chemicals for in vivo testing. In 
theory, under prioritization, all chemicals would still need to 
be tested, just in a different order. However, due to resource 
constraints, chemicals of lower concern may never be tested in 
practice. In the proposed framework, only a subset of chemicals 
would likely be elevated for additional testing in successive tiers 
based on the MOE, resulting in a significant monetary, time, and 
animal savings. However, it should be noted that depending on 
the needs of a given regulatory program, the appropriate “cap-
ture rate” for testing at each tier could be established, based on 
transparent delineation of considerations addressing this aspect 
as one of the components for acceptability of MOEs.
The proposed framework and underlying data sources also 
have some potential limitations that require improvement dur-
ing the implementation of the framework. First, the current bat-
tery of in vitro assays may not represent one or more critical 
MOAs, which may falsely identify a chemical as nonselective. 
In this scenario, the POD for the chemical would be the most 
sensitive in vitro assay while the chemical may actually selec-
tively activate or inhibit a pathway, process, or macromolecule 
at a significantly lower dose. In the proposed framework, it is 
important that the initial screen for selectivity be as compre-
hensive as possible. To broaden the biological space covered 
in Tier 1, additional in vitro assays could be included from 
those reported in PubChem (Li et al., 2010). Alternatively, in 
vitro transcriptomic measurements could also be performed in 
concentration-response format across a panel of cell lines that 
express a diverse range of cellular targets and pathways (Lamb, 
2007).
The second limitation that requires improvement is the prop-
erties associated with the current ToxCast in vitro assays. The 
limitations of these properties have been previously discussed 
(Judson et  al., 2011; Thomas et  al., 2012a) but include the 
lack of metabolism, use of single cell types that fail to repli-
cate tissue-level cell-cell interactions, lack of biological con-
text, and the short-term nature of the in vitro assays relative to 
responses following chronic duration exposure. As these assays 
are improved, the new assays can be incorporated into the Tier 
1 screening process.
A third limitation is related to the exposure modeling 
across the tiers. In the current state of exposure modeling, the 
environmental fate and transport models (ie, far field) are gen-
erally more mature and have been more thoroughly validated 
than the indoor and consumer exposure models (ie, near field). 
Ironically, far-field exposures are usually the least important by 
orders of magnitude when considering the aggregate exposure 
to a particular chemical. The lack of well-validated indoor and 
consumer exposure models can be at least partially attributed 
to both a lack of data on the use and the relative quantity of 
specific chemicals in various consumer products and the lack of 
measurement data for model validation (Egeghy et al., 2012). 
If exposure information is going to be used to make better 
decisions on chemical safety in either this framework or more 
generally, then the science relating to predicting indoor and 
consumer exposure needs to be improved.
A fourth limitation is adapting these new approaches to risk 
assessment of chemical mixtures. Current mixtures risk assess-
ment methods focus either on component-based approaches 
or whole mixture toxicity evaluations (EPA, 2000). The 
framework described in this manuscript is readily adapted to 
a components-based approach. For example, for the selective 
chemicals that target the same protein or pathway, in vivo rela-
tive potency factors could be estimated using the results from 
the associated in vitro assays and IVIVE pharmacokinetic mod-
eling to convert in vitro assay concentrations to applied doses. 
Mixtures risk estimates could then be derived using a relative 
potency factor approach similar to the toxic equivalency fac-
tors used for dioxins and dioxin-like chemicals (Van den Berg 
et al., 2006). Alternatively, a hazard index approach could be 
applied to all chemicals of concern (EPA, 2000). A hazard quo-
tient could be estimated by dividing the estimate of the human 
exposure by the Tier 1 reference value for each chemical. The 
cumulative hazard index is then estimated by summing the 
hazard quotients for all chemicals of concern. If the hazard 
index is > 1, this would indicate possible exposures of concern. 
Finally, the new in vitro approaches are also well suited for 
whole mixtures toxicity evaluation. The advantage of in vitro 
methods is that large numbers of relevant mixtures could be 
evaluated for biological activity. The proposed in vitro cumu-
lative risk approach has many of the same limitations as the 
in vitro risk approach for individual chemicals. Although this 
proposed in vitro cumulative risk approach is theoretically pos-
sible, additional experimental data needs to be collected using 
this approach prior to application.
In other initiatives, frameworks have or are being developed 
that should be considered as complementary or congruent to 
that proposed here. For example, the Health and Environmental 
Sciences Institute (HESI) RISK21 project has proposed a more 
general and overarching scheme that easily incorporates the 
tiered evaluation approaches in this proposed framework. The 
WHO framework on MOA is currently being updated to reflect 
increasing experience in hypothesizing potential effects based 
on information pertaining to putative key events in established 




In summary, the proposed framework provides a risk-based, 
rapid, cost-effective, and animal-sparing means to evaluate 
chemicals for safety. The framework represents only an ini-
tial step that can be iteratively refined along the way to a fully 
knowledge-based approach for evaluating chemical safety. 
Progress toward a better future in chemical safety assessment 
will require implementation of pragmatic approaches, such as 
the proposed framework or one similar to it, by national regula-
tory agencies, cooperation of international organizations such as 
the Organization for Economic Co-operation and Development 
(OECD), and stakeholder education and involvement.
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